BackCTI BioPharma Overview

CTI BioPharma Long Term Debt

CTI BioPharma's long-term debt is $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00
100.00% YoYΔ $-58.59M vs prior year quarter

Peer trimmed avg / median

Loading

CTI BioPharma Long Term Debt History

Loading

CTI BioPharma vs. peers: Long Term Debt Comparison

Loading

CTI BioPharma Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

CTI BioPharma (CTIC) FAQ

The latest long-term debt for CTIC is $0 as of March 2023. That compares with $59M in the prior-year period — down 100.0% year over year. Investors often review this figure alongside CTI BioPharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, CTIC's long-term debt moved from $59M to $0 — a 100.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CTI BioPharma's operating scale or balance-sheet position.

A long-term debt figure of $0 for CTIC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CTIC's long-term debt ($0), review year-over-year change from $59M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack CTI BioPharma's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.